phosphatidylinositol glycan anchor biosynthesis class F pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PIGFP2 profile across patient tissues and cancer cell-line models. PIGFP2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PIGFP2 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, PIGFP2 RNA expression shows 8,197 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, COAD, and LSCC as cancer lineages where PIGFP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIGFP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIGFP2 survival associations across molecular data types. PIGFP2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIGFP2 RNA expression–survival associations across cancer types. High PIGFP2 expression shows unfavorable associations in LUSC, SKCM, ESCA, READ, CESC and BLCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for PIGFP2 RNA expression.
This table summarizes PIGFP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PIGFP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIGFP2 shows lower tumor expression in COAD. The COAD box plot shows higher PIGFP2 RNA expression in normal versus tumor tissue (log2 FC = −0.021, t-test p = .035).
This table shows molecular features associated with PIGFP2 in patient tissues and cancer cell lines. In patient samples, PIGFP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
